Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 9, 2011, Pages 1379-1396

  Xu, Jianmin ^a   Qin, Xinyu ^a   Wang, Jianping ^b   Zhang, Suzhan ^c   Zhong, Yunshi ^a   Ren, Li ^a   Wei, Ye ^a   Zeng, Shaochong ^a   Wan, Deseng ^b   Zheng, Shu ^c  

^a FUDAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c No2 Affiliated Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CHINESE; CHINESE MEDICINE; COLORECTAL CANCER; COLORECTAL SURGERY; DIAGNOSTIC ACCURACY; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER RESECTION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RADIATION DOSE; RADIOFREQUENCY ABLATION; RISK REDUCTION; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CHINA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS; LIVER NEOPLASMS; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC;

EID: 80054742886     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-0999-8     Document Type: Article

References (192)

1. Abdalla EK (2009) Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg 197:737-739
2. Abdalla EK, Vauthey JN (2008) Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful? Dig Surg 25:421-429
3. Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastasis. Ann Surg 239:818-825
4. Adam R (2003) Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14(Suppl 2):ii13-ii16 (Pubitemid 36874133)
5. Adam R (2004) Current surgical strategies for the treatment of colorectal cancer liver metastases. Eur J Cancer Suppl 2:21-26 (Pubitemid 38726104)
6. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
7. Adam R, Aloia T, Levi F et al (2007a) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593-4602 (Pubitemid 350035318)
8. Adam R, Miller R, Pitombo M et al (2007b) Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am 16:525-536 (Pubitemid 46990942)
9. Adam R, Wicherts DA, de Haas RJ et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26:1635-1641
10. Alberts SR, Wagman LD (2008) Chemotherapy for colorectal cancer liver metastases. Oncologist 13:1063-1073
11. Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983-4990 (Pubitemid 46631400)
12. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634
13. Andre L, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovourin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116
14. Antonion A, Lovegrove RE, Tilney HS et al (2007) Meta analysis of clinical outcome after first and second liver resection for colorectal metastases. Surgery 141:9-18 (Pubitemid 44918087)
15. Arru M, Aldrighetti L, Castoldi R et al (2008) Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg 32:93-103 (Pubitemid 50004245)
16. Benoist S, Nordlinger B (2007) Neoadjuvant treatment before resection of liver metastases. Eur J Surg Oncol 33(Suppl 2):S35-S41 (Pubitemid 350216631)
17. Benoist S, Nordlinger B (2009) The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol 16:2385-2390
18. Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939-3945 (Pubitemid 46630742)
19. Bentrem DJ, DeMatteo RP, Blumgart LH (2005) Surgical therapy for metastatic disease to the liver. Ann Rev Med 56:139-156 (Pubitemid 40299777)
20. Berber E, Tsinberg M, Tellioglu G et al (2008) Resection versus laparoscopic radio frequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 12:1967-1972
21. Bilchik AJ, Wood TF, Allegra DP (2001) Radiofrequency ablation of unresectable hepatic malignancies: lesson learned. Oncologist 6:24-33 (Pubitemid 32155813)
22. Bipat S, van Leeuwen MS, Ijzermans JN et al (2007) Evidence-base guideline on management of colorectal liver metastases in the Netherlands. Neth J Med 65:5-14 (Pubitemid 46152289)
23. Blatzer D, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end poin after resection of hepatic colorectal metastases. J Clin Oncol 17:5299
24. Bokemeyer C, Bandarenko I, Mahkson A et al (2009) Fluorouracil leucovorin and oxaliplatin with or without cetuximab in the firstline treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
25. Borschitz T, Wachtlin D, Möhler M et al (2008) Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 15:712-720
26. Bouganim N, Ang C, Kavan P et al (2008) Perioperative bevacizumab containing chemotherapy for colorectal liver metastases. J Clin Oncol 26: abstr 15073
27. Cals L, Rixe O, Francois E et al (2004) Dose-finding study of weekly 24 h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 15:1018-1024 (Pubitemid 39089777)
28. Capussotti L, Ferrero A, Vigano L et al (2007) Major liver resection synchronous with colorectal surgery. Ann Surg Oncol 14:195-201 (Pubitemid 44954289)
29. Carpizo DR, D'Angelica M (2009) Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol 16:2411-2421
30. Cassidy J, Clarke s, Diaz-Rubio D et al (2007) XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. In: 2007 gastrointestinal cancers symposium. Abstract 270
31. Cassidy J, Cunningham D, Berry SR et al (2008) Surgery with curative intent in patients treated with first-line chemotherapy + bevacizumab for metastatic colorectal cancer: first BEAT and NO16966. J Clin Oncol 26(Suppl):4022
32. Ceelen WP, van Nieuwenhove Y, Fierens K (2009) Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (Review). Cochrane Database Syst Rev (1): CD006041
33. Cervantes A, Roselló S, Rodríguez-Braun E et al (2008) Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol 19(Suppl 7):vii266-272
34. Chau I, Chan S, Cunningham D (2003) Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. Clin colorectal Cancer 3:19-33 (Pubitemid 37220784)
35. Chiappa A, Bertani E, Makuuchi M et al (2009) Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology 56(91-92):829-834
36. Choti MA (2009) Chemotherapy-associated hepatotoxicity: do we need to be concerned? Ann Surg Oncol 16:2391-2394
37. Clancy TE, Dixon E, Perlis R et al (2005) Hepatic arterial infusion after curative resection of colorectal cancer metastases: a metaanalysis of prospective clinical trials. J Gastrointest Surg 9:198-206 (Pubitemid 40202977)
38. Cleary JM, Tanabe KT, Lauwers GY et al (2009) Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 14:1095-1105
39. Coenegrachts K, De Geeter F, ter Beek L et al (2009) Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol 19:370-379
40. Colucci G, Gebbia V, Paoletti G et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875 (Pubitemid 46223991)
41. Coskun U, Buyukberber S, Yaman E et al (2008) Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma 55:65-70
42. Covey AM, Brown KT, Jamagin WR et al (2008) Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 247:451-455
43. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345 (Pubitemid 38944402)
44. Curley SA, Izzo F (2002) Radiofrequency ablation of hepatocellular carcinoma. Minerva Chir 57:165-176 (Pubitemid 34496111)
45. D'Angelica M, Kornprat P, Gonen M et al (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14:759-765 (Pubitemid 46175324)
46. De Gramout A, Boni C, Navarro M et al (2007) Oxaliplatin/5-FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years. J Clin Oncol 25:18S (June 20 suppl). Abstract 4007
47. De Jong MC, Pulitano C, Ribero D et al (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250:440-448
48. De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wildtype state predicts survival and is associated to early radiological response in metastastic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515 (Pubitemid 351325672)
49. Delbeke D, Martin WH (2004) PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 34:209-223 (Pubitemid 38887176)
50. Desch CE, Benson AB, Somerfield MR et al (2005) Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512-8519
51. Di Stefano DR, de Baere T, Denys A et al (2005) Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 234:625-630 (Pubitemid 40139940)
52. Díaz Rubio E, Tabernero J, van Cutsem E et al (2005) Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 23(16 suppl):254s
53. Eble MJ, Gademann G, Wannenmacher M et al (1993) The value of radiotherapy for liver metastases. Strahlenther-Onkol 169:459-468
54. Elias D, Youssef O, Sideris L et al (2004a) Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86:4-9 (Pubitemid 38490093)
55. Elias D, Youssef O, Sideris L et al (2004b) Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86:4-9 (Pubitemid 38490093)
56. Elias D, Liberale G, Vernerey D et al (2005) Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12:900-909 (Pubitemid 41504223)
57. Elias D, Benizri E, Pocard M et al (2006a) Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol 32:632-636 (Pubitemid 44064000)
58. Elias D, Di Pietroantonio D, Gachot B et al (2006b) Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. Gastroenterol Clin Biol 30:823-827 (Pubitemid 44196101)
59. Ellis LM, Curley SA, Grothey A (2005) Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23:4853-4855 (Pubitemid 46223989)
60. Fahy BN, D'Angelica M, DeMatteo RP et al (2009) Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention. Ann Surg Oncol 16:361-370
61. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOX-IRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as frst-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676 (Pubitemid 46797946)
62. Fernandez FG, Ritter J, Goodwin JW et al (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845-853 (Pubitemid 40744790)
63. Folprecht G, Gruenberger T, Bechstein WO et al (2009) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. Nov. 24 [Epub ahead of print]
64. Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938-946 (Pubitemid 27106275)
65. Foster JH (1984) Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis 4:170-179
66. Fraker DL, Soulen M (2002) Regional therapy of hepatic metastases. Hematol Oncol Clin North Am 16:947-967 (Pubitemid 35215833)
67. Giuliante F, Ardito F, Vellone M et al (2009) Role of the surgeon as a variable in long-term survival after liver resection for colorectal metastases. J Surg Oncol 100:538-545
68. Goldberg RM (2006) Therapy for metastatic colorectal cancer. Oncologist 11:981-987 (Pubitemid 44564805)
69. Goldberg RM, Sargent DJ, Morton RF et al (2006) Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24:3347-3353 (Pubitemid 46638888)
70. Gomez D, Malik HZ, Bonney GK et al (2007) Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg 94:1395-1402 (Pubitemid 350144389)
71. Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose escalation study of single fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486-493
72. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326-5334
73. Gruenberger B, Tamandl D, Puhalla H et al (2007) Bevacizumab plus XELOX as neoadjuvant chemotherapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 25(18 suppl):179s
74. Gruenberger B, Scheithauer W, Punzengruber R et al (2008a) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8:120
75. Gruenberger B, Tamandl D, Schueller J et al (2008b) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835
76. Gruenberger T, Kaczirek K, Bergmann M et al (2008) Progressionfree survival in a phase II study of perioperative bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26: abstr 4073
77. Hao CY, Ji JF (2006) Surgical treatment of liver metastases of colorectal cancer: Strategies and controversies in 2006. Eur J Surg Oncol 32:473-483
78. Hecht JR, Mitchell E, Chidiac CJ et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy ang bevacizaumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-680
79. Hochster H, Hart LL, Ramanathan R et al (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE study. J Clin Oncol 24: NO. 18S (June 20 suppl). Abstract 3510
80. Hochster HS, Hart LL, Ramanathan RK et al (2008) Safety and effcacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26:3523-3529
81. Hoff PM, Eng C, Adinin RB et al (2006) Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-linetreatment for metastatic colorectal cancer (mCRC). ASCO Ann Meeting Proc 24(Suppl):165S
82. Homayounfar K, Liersch T, Schuetze G et al (2009) Two-stage hepatectomy (R0) with portal vein ligation-towards curing patients with extended bilobular colorectal liver metastases. Int J Colorectal Dis 24:409-418
83. Huang K, Haas-Kogan D, Weinberg V et al (2001) Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 13:895-900
84. Hur H, Ko YT, Min BS et al (2009) Comparative study of reseaction and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728-736
85. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
86. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508
87. Jaeck D (2003) The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol 10:1007-1011 (Pubitemid 40486822)
88. Jaeck D, Oussoultzoglou E, Rosso E (2007) Hepatectomy for colorectal metastases in the presence of extrahepatic disease. Surg Oncol Clin N Am 16:507-523 (Pubitemid 46990947)
89. Johal BS, Phang P, McGahan C et al (2007) Treatment patterns and outcomes of patients with pT3N0 rectal cancer in a populationbased setting. J Clin Oncol 25: No 18S (June 20 suppl). Abstract 4039
90. Jones OM, Rees M, John TG et al (2005) Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg 92:1165-1168 (Pubitemid 41284884)
91. Kabbinavar FF, Schulz J, McCleod M et al (2005a) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697-3705
92. Kabbinavar FF, Hambleton J, Mass RD et al (2005b) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712
93. Kabbinavar FF, Hurwitz HI, Yi J et al (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27:199-205
94. Kandutsch S, Klinger M, Hacker S et al (2008) Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 34:1231-1236
95. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2009) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
96. Karoui M, Penna C, Amin-Hashem M et al (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal livermetastases. Ann Surg 243:1-7 (Pubitemid 43054046)
97. Kemeny N (2006) Management of liver metastases from colorectal cancer. Oncology (Williston Park) 20:1161-1176, 1179; discussion 1179-1180, 1185-1166
98. Kemeny N, Jarnagin W, Paty P et al (2005a) Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23:4888-4896 (Pubitemid 46223994)
99. Kemeny N, Eid A, Stockman J et al (2005b) Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 91:97-101 (Pubitemid 41077048)
100. Kemeny NE, Capanu M, Fong Y et al (2008) Survival after resection of liver metastases from colorectal cancer with poor clinical risk factors using adjuvant systemic plus hepatic arterial therapy. J Clin Oncol 26: abstr 4076
101. Kesmodel SB, Ellis LM, Lin E et al (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254-5260
102. Klautke G, Fietkau R (2007) Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review. Int J Colorectal Dis 22:457-465 (Pubitemid 46488049)
103. Klinger M, Eipeldauer S, Hacker S et al (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35:515-520
104. Knudsen AR, Kannerup AS, Mortensen FV et al (2009) Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy. Acta Radiol 50:716-721
105. Koshariya M, Jagad RB, Kawamoto J et al (2007) An update and our experience with metastatic liver disease. Hepatogastroenterology 54:2232-2239
106. Kuehl H, Antoch G, Stergar H et al (2008) Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol 67:362-371
107. Lau WY, Lai EC (2007) Hepatic resection for colorectal liver metastases. Singapore Med J 48:635-639 (Pubitemid 351396793)
108. LeCouter J, Moritz DR, Li B et al (2003) Angiogenesis-independent endothelial protection of liver: role of VEGFR1. Science 299:890-893 (Pubitemid 36182447)
109. Leonard GD, Brenner B, Kemeny NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:2038-2048 (Pubitemid 46211384)
110. Lochan SA, White DM, Manas (2007) Liver resection for colorectal liver metastasis. Surg Oncol 16:33-45 (Pubitemid 46881287)
111. Locker GY, Hamiton S, Harris J et al (2006) ASCO 2006 update of recommendations for use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327 (Pubitemid 46631379)
112. Lu DS, Raman SS, Limanond P et al (2003) Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 14:1267-1274 (Pubitemid 37266660)
113. Malik HZ, Farid S, Al-Mukthar A et al (2007) A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study. Ann Surg Oncol 12:3519-3526 (Pubitemid 350160110)
114. Masi G, Loupakis F, Pollina L et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOL-FOXIRI) followed by radical surgery of metastases. Ann Surg 249:420-425
115. Mehta NN, Ravikumar R, Coldham CA et al (2008) Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol 34:782-786
116. Mentha G, Majno PE, Andres A et al (2006) Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 93:872-878 (Pubitemid 44035261)
117. Mentha G, Majno P, Terraz S et al (2007) Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol 33(Suppl 2):S76-S83 (Pubitemid 350216628)
118. Miller G, Biernacki P, Kemeny NE et al (2007) Outcomes after resection of synchronous or metachronous hepatic and pulmonary metastases. J Am Coll Surg 205:231-238 (Pubitemid 47095434)
119. Mocellin S, Pilati P, Lise M et al (2007) Hepatic arterial infusion (HAI) compared to systemic chemotherapy for the treatment of unresectable livermetastases from colorectal carcinoma: a systematic review and meta-analysis of randomized controlled trials. J Clin Oncol 25(18 suppl):626 s
120. Mocellin S, Pasquali S, Nitti D (2009) Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 4:CD007823
121. Mohiuddin M, Chen E, Ahmad N (1996) Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 14:722-728 (Pubitemid 26085515)
122. Moug SJ, Horgan PG (2007) The role of synchronous procedures in the treatment of colorectal liver metastases. Surg Oncol 16:53-58 (Pubitemid 46881288)
123. Nakano H, Oussultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal metastases receiving preoperative chemotherapy. Ann Surg 247:118-124
124. Neeleman N, Andersson R (1996) Repeated liver resection for recurrent cancer. Br J Surg 83:893-901 (Pubitemid 26228200)
125. Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77:1254-1262 (Pubitemid 26102322)
126. Nordlinger B, Sorbye H, Collette L et al (2007) Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of perioperative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 5(Suppl. 18):LBA5
127. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016 (Pubitemid 351392040)
128. Nordlinger B, Van Cutsem E, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985-992
129. Okuno k (2007) Surgical treatment for digestive cancer. Current issues-colon cancer. Dig Surg 24(2):108-114 (Pubitemid 46788276)
130. Otchy D, Hyman NH, Simmang C et al (2004) Practice parameters for colon cancer. Dis Colon Rectum 47:1269-1284 (Pubitemid 39180201)
131. Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722
132. Pawlik TM, Olino K, Gleisner AL et al (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860-868
133. Peeters KCMJ, Marijinen CAM, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years. Ann Surg 246:693-701
134. Pelosi E, Deandreis D (2007) The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol 33:1-6 (Pubitemid 46156622)
135. Poultsides GA, Servais EL, Saltz LB et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379-3384
136. Raoul JL, Van Laethem JL, Peeters M et al (2009) Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLF-IRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 9:112
137. Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96-106 (Pubitemid 350267242)
138. Reddy SK, Barbas AS, Clary BM (2009) Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management? Ann Surg Oncol 16:2395-2410
139. Reuter NP, Woodall CE, Scoggins CR et al (2009) Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivaient? J Gastrointest Surg 13:486-491
140. Rex DK, Kahi CJ, Levin B et al (2006) Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on colorectal cancer. CA Cancer J Clin 56:160-167; quiz 185-166 (Pubitemid 43847926)
141. Robertson JM, McGinn CJ, Walker S et al (1997) A phase l trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. J Rad Oncol Biol Phys 39:1087-1092 (Pubitemid 27506161)
142. Rodriguez-Moranta F, Salo J, Arcusa A et al (2006) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 24:386-393 (Pubitemid 46630457)
143. Roohipour R, Patil S, Goodman KA et al (2008) Squamous-cell carcinoma of the canal: predictors of treatmant outcome. Dis Colon Rectum 51:147-153
144. Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299-304 (Pubitemid 46323097)
145. Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572-1578
146. Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
147. Samantas E, Dervenis C, Rigatos SK (2007) Adjuvant chemotherapy for colon cancer: evidence on improvement in survival. Dig Dis 25:67-75 (Pubitemid 46478244)
148. Sargent D, Sobrero A, Grothey A et al (2009) Evidence for cure by adjuvant therapy in colon cancer: obeservations based on indiviual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 27:872-877
149. Sarpel U, Bonavia AS, Grucela A et al (2009) Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann Surg Oncol 16:379-384
150. Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173-180 (Pubitemid 41254420)
151. Schefter TE, Kavanagh BD, Timmerman RD et al (2005) A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62:1371-1378 (Pubitemid 40982057)
152. Sebag-Montefiore D, Stephens RJ, Steele R et al (2009) Prooperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a muticentre, randomised trial. Lancet 373:811-820
153. Sharma S, Camci C, Jabbour N (2008) Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg 15:570-580
154. Shimada H, Tanaka K, Endou I et al (2009) Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg 394:973-983
155. Shoup M, Gonen MD, Angelica M et al (2003) Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7:325-330 (Pubitemid 36875770)
156. Siegel R, Burock S, Wernecke KD et al (2009) Preoperative shortcourse radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 9:50
157. Siperstein AE, Barber E, Ballem N, Parikh T (2007) Survival after radiofrequency ablation of colorectal liver metastases-10 year experience. Ann Surg 246:559-567
158. Slupski M, Wlodarczyk Z, Jasinski M et al (2009) Outcomes of simultaneous and delayed resections of synchronous colorectal liver metastases. Can J Surg 52:E241-E244
159. Souglakos J, Androulakis N, Syrigos K et al (2006) FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer 94:798-805
160. Soumarova R, Skrovina M, Bartos J et al (2009) Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum-Toxicity and complications of the treatment. Eur J Surg Oncol Oct. 29. [Epub ahead of print]
161. Tan BR, Zubal B, Hawkins W et al (2009) Preoperative FOLFOX pius cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases. In: gastrointestinal cancers symposium. Abstract 497
162. Tanaka K, Adam R, Shimada H et al (2003) Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 90:963-969 (Pubitemid 37026325)
163. Tanaka K, Shimada H, Matsuo M et al (2007) Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. Eur J Surg Oncol 33:329-335 (Pubitemid 46488669)
164. Taniai N, Akimaru K, Yoshida H, Tajiri T (2007) Surgical treatment for better prognosis of patients with liver metastases from colorectal cancer. Hepatogastroenterology 54:1805-1809 (Pubitemid 350068482)
165. Tejpar S, Peeters M, Humblet Y et al (2008) Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVERSET experience (preliminary data). J Clin Oncol 26(may 20 suppl): Abstract 4001
166. Timmerman RD, Bizekis CS, Pass HI et al (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59:145-170
167. Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572
168. Tomlinson JS, Jarnagin WR, DeMatteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575-4580 (Pubitemid 350035315)
169. Tournigand C, Andre T, Acille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GEROR study. J Clin Oncol 22:229-237 (Pubitemid 41095086)
170. Turrini O, Viret F, Guiramand J et al (2007) Strategies for the treatment of synchronous liver metastasis. Eur J Surg Oncol 33:735-740 (Pubitemid 47029680)
171. Tveit KM, Wiig JN, Olsen DR et al (1997) Combined modality treatment including intraoperative radiotherapy in locally advanced and recurrent rectal cancer. Radiother Oncol 44:277-282 (Pubitemid 27405153)
172. Vadeyar HJ (2007) Current therapeutic options for colorectal liver metastases. Indian J Gastroenterol 26:26-29 (Pubitemid 46708798)
173. Van Cutsem E, Köhne CH, Hitre E et al (2009a) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417
174. Van Cutsem E, Rivera F, Berry S et al (2009b) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842-1847
175. Van den Eynde M, Hendlisz A (2009) Treatment of colorectal liver metastases: a review. Rev Recent Clin Trials 4(1):56-62
176. Van der Voort van Zijp J, Hoekstra HJ, Basson MD (2008) Evolving management of colorectal cancer. World J Gastroenterol 14:3956-3967
177. Vauthey JN, Zorzi D, Pawlik TM (2005) Making unresectable hepatic colorectal metastases resectable-does it work? Semin Oncol 32(Suppl 9):S118-S122 (Pubitemid 43080932)
178. Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072 (Pubitemid 46622116)
179. Venook A, Hollis D et al (2006) Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin (FOLFOX) cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 24(18 suppl):148s
180. Vermaas M, Gosselink MP, Ferenschild FTJ et al (2007) Introduction of preoperative radiotherapy in the treatment of operable rectal cancer in the Southwest region of the Netherlands. Eur J Surg Oncol 33:862-867 (Pubitemid 47279048)
181. Vibert E, Canedo L, Adam R (2005) Strategies to treat primary unresectable colorectal liver metastases. Semin Oncol 32(6 suppl 8):33-39
182. Warwick R, Page R (2007) Resection of pulmonary metastases from colorectal carcinoma. Eur J Surg Oncol 33:S59-S63 (Pubitemid 350216633)
183. Weber JC, Bachellier P, Oussoultzoglow E et al (2003) Simultaneous resection of colorectal primary tumor and synchronous liver metastases. Br J Surg 90:956
184. Welch S, Spithoff K, Rumble RB et al (2009) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol [Epub ahead of print]
185. Welsh FK, Tilney HS, Tekkis PP et al (2007) Safe liver resection following chemotherapy for colorectalmetastases is amatter of timing. Br J Cancer 96:1037-1042 (Pubitemid 46608314)
186. Wolpin BM, Mayer RJ (2008) Systemic treatment of colorectal cancer. Gastroenterology 134(5):1296-1310
187. Xu J, Zhong Y, Niu W et al (2007) Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg 245:583-590 (Pubitemid 46555662)
188. Yan TD, Padang R, Xia H et al (2006) Management of involved or close resection margins in 120 patients with colorectal liver metastases: edge cryotherapy can achieve longterm survival. Am J Surg 191:735-742 (Pubitemid 43729403)
189. Ychou M, Hohenberger W, Thezenas S et al (2008) Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU + irinotecan (LV5FU + IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). J Clin Oncol 26: abstr LBA4013
190. Yu T-K, Bhosale PR, Crane CH et al (2008) Patterns of locaregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Rad Oncol Biol Phys 71:1175-1180
191. Zelck L, Bugat R, Cherqui D et al (2003) Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in nonresectable hepatic metastases from colorectal cancer. Ann Oncol 14:1537-1542 (Pubitemid 37304610)
192. Zorzi D, Kishi Y, Maru DM et al (2009) Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases. J Clin Oncol; Abstract 295